Author:
Igelman Sean,Kurta Anastasia O.,Sheikh Umar,McWilliams Ashley,Armbrecht Eric,Jackson Cullison Stephanie R.,Kress Douglas W.,Smith Anna,Castelo-Soccio Leslie,Treat James,Boothe William D.,Diaz Lucia Z.,Levy Moise L.,Patel Avni,Lee Lara Wine,Fraile-Alonso M. Carmen,Antaya Richard J.,Shah Sonal,Kittler Nicole,Arkin Lisa,Siegfried Elaine
Reference9 articles.
1. Associations of childhood eczema severity: a US population-based study;Silverberg;Dermatitis,2014
2. Two phase 3 trials of dupilumab versus placebo in atopic dermatitis;Simpson;N Engl J Med,2016
3. Simpson EL, Paller AS, Siegfried EC, et al. Dupilumab efficacy and safety in adolescents with moderate-to-severe atopic dermatitis: results from a multicenter, randomized, placebo-controlled, double-blind, parallel-group, phase 3 study. Presented at the 27th Annual European Academy of Dermatology and Venereology Conference. Paris, France. 2018.
4. Dupilumab provides important clinical benefits to patients with atopic dermatitis who do not achieve clear or almost clear skin according to the Investigator's Global Assessment: a pooled analysis of data from two phase III trials;Silverberg;Br J Dermatol,2019
Cited by
47 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献